Company Overview
| Stock Name | Heartcare-B |
|---|---|
| Stock Code | 06609 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是一家創新型神經介入醫療器械公司,產品組合包括神經介入及心臟醫療器械,憑藉研發、生產及商業化能力,致力降低中國乃至全球的腦卒中死亡率並改善預後。 |
| Listing Date | 2021-08-20 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 上海市自由貿易試驗區臨港新片區正博路356號38幢第1層、第3層 |
| Business Address (Hong Kong) | 德輔道中161號香港貿易中心19樓1903-4室 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | strokemedical.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 171.00 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 50 shares |
| Entry Threshold | HK$ 8,550 |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2021-08-10 to 2021-08-13 |
| Global Offering Shares | 6,601,850 shares |
| HK Public Offer Shares (Initial) | 660,200 shares (10.0%) |
| Public Offer Lots (Initial) | 13,204lots (Pool A6,602lots,Pool B6,602lots) |
| International Placing Shares (Initial) | 5,941,650 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 38,834,408 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 45.5% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 1,128,916,350 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 50 | HK$ 8,550 |
| 2 lots | 100 | HK$ 17,100 |
| 3 lots | 150 | HK$ 25,650 |
| 4 lots | 200 | HK$ 34,200 |
| 5 lots | 250 | HK$ 42,750 |
| 6 lots | 300 | HK$ 51,300 |
| 7 lots | 350 | HK$ 59,850 |
| 8 lots | 400 | HK$ 68,400 |
| 9 lots | 450 | HK$ 76,950 |
| 10 lots | 500 | HK$ 85,500 |
| 12 lots | 600 | HK$ 102,600 |
| 14 lots | 700 | HK$ 119,700 |
| 16 lots | 800 | HK$ 136,800 |
| 18 lots | 900 | HK$ 153,900 |
| 20 lots | 1,000 | HK$ 171,000 |
| 30 lots | 1,500 | HK$ 256,500 |
| 40 lots | 2,000 | HK$ 342,000 |
| 50 lots | 2,500 | HK$ 427,500 |
| 60 lots | 3,000 | HK$ 513,000 |
| 70 lots | 3,500 | HK$ 598,500 |
| 80 lots | 4,000 | HK$ 684,000 |
| 90 lots | 4,500 | HK$ 769,500 |
| 100 lots | 5,000 | HK$ 855,000 |
| 120 lots | 6,000 | HK$ 1,026,000 |
| 140 lots | 7,000 | HK$ 1,197,000 |
| 160 lots | 8,000 | HK$ 1,368,000 |
| 180 lots | 9,000 | HK$ 1,539,000 |
| 200 lots | 10,000 | HK$ 1,710,000 |
| 300 lots | 15,000 | HK$ 2,565,000 |
| 400 lots | 20,000 | HK$ 3,420,000 |
| 500 lots | 25,000 | HK$ 4,275,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 600 lots | 30,000 | HK$ 5,130,000 |
| 700 lots | 35,000 | HK$ 5,985,000 |
| 800 lots | 40,000 | HK$ 6,840,000 |
| 900 lots | 45,000 | HK$ 7,695,000 |
| 1,000 lots | 50,000 | HK$ 8,550,000 |
| 1,200 lots | 60,000 | HK$ 10,260,000 |
| 1,400 lots | 70,000 | HK$ 11,970,000 |
| 1,600 lots | 80,000 | HK$ 13,680,000 |
| 1,800 lots | 90,000 | HK$ 15,390,000 |
| 2,000 lots | 100,000 | HK$ 17,100,000 |
| 3,000 lots | 150,000 | HK$ 25,650,000 |
| 4,000 lots | 200,000 | HK$ 34,200,000 |
| 6,602 lots | 330,100 | HK$ 56,447,100 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| HK Market Cap | HK$ 1.52B |
| Est. Threshold | HK$ 9.39B |
| Analysis Result | HK market cap below threshold, need +516% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 6,640,683,768 |
|---|---|
| H-Share Market Cap (at Offer Price) | HK$ 5,397,752,484 |
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 虧損人民幣216.2百萬元 |
| Period-End Cash Balance | 人民幣632.4百萬元 |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2019 | 2020 |
|---|---|---|
| Revenue | 0 | 14,562 |
| Cost of sales | 0 | -7,475 |
| Gross profit | 0 | 7,087 |
| Other income and gains, net | 3,108 | 6,000 |
| Selling and distribution expenses | -1,039 | -14,278 |
| Administrative expenses | -26,395 | -141,869 |
| Net finance costs | -62 | -1,604 |
| Profit before tax | -75,498 | -216,183 |
| Income tax expense | 0 | 0 |
| Profit for the year | -75,498 | -216,183 |
| Profit attributable to owners | -75,498 | -213,664 |
Balance Sheet
| Item | 2019 | 2020 |
|---|---|---|
| Cash and cash equivalents | 25,548 | 632,418 |
| Trade and bills receivables | 0 | 0 |
| Inventories | 247 | 8,638 |
| Total current assets | 64,269 | 661,782 |
| Total assets | 91,283 | 773,631 |
| Total current liabilities | 4,313 | 36,612 |
| Total liabilities | 10,210 | 82,596 |
| Total equity | 81,073 | 691,035 |
| Equity attributable to owners | 81,073 | 681,368 |
Cash Flow Statement
| Item | 2019 | 2020 | 2021-03 |
|---|---|---|---|
| Net cash from operating activities | -32,291 | -74,814 | |
| Net cash from investing activities | -45,293 | -4,534 | |
| Net cash from financing activities | 94,499 | 686,218 | |
| Net increase in cash | 16,915 | 606,870 | |
| Depreciation of PP&E | 1,480 | 4,952 | 1,406 |
| Depreciation of right-of-use assets | 862 | 3,433 | 864 |
| Purchase of PP&E | -20,815 | -15,605 | -11,287 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 129.0 |
|---|---|
| First Day Open | HK$ 141.2 |
| First Day Change | -24.56% |
| First Day Volume | 2053800.0 |
| First Day Turnover | 281742000.0 |
| Use of Proceeds | 1、約45.3%或約459.7百萬港元預期將分配至我們的核心產品;
2、約39.9%所或約404.9百萬港元預期將分配至我們管線內的其他在研產品;
3、約4.8%或約48.7百萬港元用于為透過內部研究提升研發能力及持續擴充產品組合提供資金;
4、約10.0%或約101.5百萬港元預期將用作營運資金及一般企業用途。 |
Underwriting Syndicate
Joint Bookrunners (3)
Joint Lead Managers (3)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 3W Funds | 23,324,400 HKD | — | 2.07% | — | 6 months | 2022-02-20 |
| 2 | Aspex Master Fund | 77,745,150 HKD | — | 6.89% | — | 6 months | 2022-02-20 |
| 3 | Boyu Capital Opportunities Master Fund | 77,745,150 HKD | — | 6.89% | — | 6 months | 2022-02-20 |
| 4 | Goldstream Healthcare Focus Fund SP | 23,324,400 HKD | — | 2.07% | — | 6 months | 2022-02-20 |
| 5 | Lake Bleu Prime Healthcare Master Fund Limited | 77,745,150 HKD | — | 6.89% | — | 6 months | 2022-02-20 |
| 6 | LYFE CAPITAL FUND III (DRAGON), L.P. | 38,868,300 HKD | — | 3.44% | — | 6 months | 2022-02-20 |
| 7 | Octagon Investments Master Fund LP | 77,745,150 HKD | — | 6.89% | — | 6 months | 2022-02-20 |
| 8 | Sage Partners Master Fund | 38,868,300 HKD | — | 3.44% | — | 6 months | 2022-02-20 |
| 9 | Superstring Capital Master Fund LP | 38,868,300 HKD | — | 3.44% | — | 6 months | 2022-02-20 |
| 10 | The Valliance Fund | 38,868,300 HKD | — | 3.44% | — | 6 months | 2022-02-20 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 王國輝 | — |
| Company Secretary | 張涵 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 王國輝先生、心瑋投資、楷遠投資、瑋鈺上海及瑋鋆上海被視為一組單一最大股東,合共持有本公司已發行股本約29.20%;LYFE Capital Management Limited持有約13.06%。 |
|---|




